Galderma presented new long-term data at EADV 2026 showing sustained improvements in skin lesions, itch and quality of life for patients with moderate-to-severe atopic dermatitis.
Key points
•91% achieved EASI-75 improvement
•67% achieved near-complete skin clearance
•Long-term safety profile consistent
At the 2026 European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Galderma shared three-year data from the ARCADIA long-term extension study on Nemluvio. The findings indicate sustained benefits for patients with atopic dermatitis.
Up to 91% of participants achieved significant improvement in eczema severity, and up to 67% experienced near-complete skin clearance by Week 152. Additionally, the treatment was well-tolerated, with no new safety concerns identified after three years.
Further analyses highlighted that itch and skin lesions are key drivers of sleep disturbance and quality of life impairment in atopic dermatitis patients.
